These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 35192655

  • 1. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD, Browne EN, Gundacker HM, Hawley I, Chen BA, Hoesley C, Scheckter R, Piper J, Singh D, Song M, Liu A, van der Straten A.
    PLoS One; 2022; 17(2):e0263664. PubMed ID: 35192655
    [Abstract] [Full Text] [Related]

  • 2. Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.
    Watnick D, Keller MJ, Stein K, Bauman LJ.
    AIDS Behav; 2018 Feb; 22(2):421-436. PubMed ID: 29147810
    [Abstract] [Full Text] [Related]

  • 3. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
    Dobkin A, McWalters J, Barnett R, Ray LL, Espinoza L, McGinn AP, Atrio JM, Keller MJ.
    Sex Transm Dis; 2020 Dec; 47(12):819-824. PubMed ID: 33186337
    [Abstract] [Full Text] [Related]

  • 4. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 5. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, Gati Mirembe B, Mhlanga F, Hunidzarira P, Mansoor LE, Siva S, Govender V, Makanani B, Naidoo L, Singh N, Nair G, Chinula L, Parikh UM, Mellors JW, Balán IC, Ngure K, van der Straten A, Scheckter R, Garcia M, Peda M, Patterson K, Livant E, Bunge K, Singh D, Jacobson C, Jiao Y, Hendrix CW, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Torjesen K, Nel A, Rosenberg Z, Soto-Torres LE, Hillier SL, Brown ER, MTN-025/HOPE Study Team.
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [Abstract] [Full Text] [Related]

  • 6. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, Steytler J, van der Ryst E, Craig C, Louw C, Gwetu T, Mabude Z, Kotze P, Moraba R, Tempelman H, Gill K, Kusemererwa S, Bekker LG, Devlin B, Rosenberg Z, DREAM Study Team.
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [Abstract] [Full Text] [Related]

  • 7. Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls.
    Baker Z, Javanbakht M, Moore J, Brosnan H, Squires K, Bunge K, Zimet G, Mensch B, Soto-Torres L, Kapogiannis B, Levy L, Hoesley C, Reirden D, Gaur A, Mayer K, Futterman D, Gorbach P.
    J Acquir Immune Defic Syndr; 2021 Jul 01; 87(3):944-950. PubMed ID: 33675614
    [Abstract] [Full Text] [Related]

  • 8. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET, Noguchi LM, Dai JY, Pan J, Biggio J, Hendrix C, Isaacs K, Watts DH, Schwartz JL, Piper J, Beigi R.
    AIDS Behav; 2018 Feb 01; 22(2):402-411. PubMed ID: 28550377
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.
    van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, Bekker L, Ganesh S, Young K, Romano J, Nel A, Woodsong C.
    AIDS Behav; 2012 Oct 01; 16(7):1775-86. PubMed ID: 22644068
    [Abstract] [Full Text] [Related]

  • 11. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
    Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, Owino F, van der Straten A, TRIO Study Team.
    AIDS Behav; 2018 Aug 01; 22(8):2662-2673. PubMed ID: 29560570
    [Abstract] [Full Text] [Related]

  • 12. Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.
    Roberts ST, Hawley I, Luecke E, Mensch B, Wagner T, Hoesley C, McClure T, Dominguez Islas CP, Piper JM, Liu AY, van der Straten A.
    J Womens Health (Larchmt); 2022 Jul 01; 31(7):1029-1039. PubMed ID: 34665672
    [Abstract] [Full Text] [Related]

  • 13. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E, Tauya T, Reddy K, Mirembe BG, Woeber K, Palanee-Phillips T, Zimba C, Atujuna M, Montgomery ET, MTN-020/ASPIRE Study Team.
    AIDS Behav; 2020 Mar 01; 24(3):866-880. PubMed ID: 31111297
    [Abstract] [Full Text] [Related]

  • 14. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.
    Duby Z, Katz AWK, Browne EN, Mutero P, Etima J, Zimba CC, Woeber K, Atujuna M, Reddy K, van der Straten A, MTN-020/ASPIRE Study Team.
    AIDS Behav; 2020 Feb 01; 24(2):617-628. PubMed ID: 31030301
    [Abstract] [Full Text] [Related]

  • 15. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
    Shapley-Quinn MK, Laborde N, Luecke E, Hoesley C, Salata RA, Johnson S, Nel A, Soto-Torres L, Chen BA, van der Straten A.
    AIDS Patient Care STDS; 2022 Mar 01; 36(3):97-105. PubMed ID: 35289688
    [Abstract] [Full Text] [Related]

  • 16. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW.
    AIDS Behav; 2013 Feb 01; 17(2):737-47. PubMed ID: 23065145
    [Abstract] [Full Text] [Related]

  • 17. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
    Laborde ND, Pleasants E, Reddy K, Atujuna M, Nakyanzi T, Chitukuta M, Naidoo S, Palanee-Phillips T, Baeten JM, Montgomery ET, MTN-020/ASPIRE Study Team.
    AIDS Behav; 2018 Feb 01; 22(2):437-446. PubMed ID: 29151197
    [Abstract] [Full Text] [Related]

  • 18. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, Laborde N, Soto-Torres L.
    AIDS Behav; 2015 May 01; 19(5):784-93. PubMed ID: 25416076
    [Abstract] [Full Text] [Related]

  • 19. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
    Smith JM, Moss JA, Srinivasan P, Butkyavichene I, Gunawardana M, Fanter R, Miller CS, Sanchez D, Yang F, Ellis S, Zhang J, Marzinke MA, Hendrix CW, Kapoor A, Baum MM.
    PLoS One; 2017 May 01; 12(10):e0185946. PubMed ID: 28982161
    [Abstract] [Full Text] [Related]

  • 20. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM, Rosen RK, Vargas SE, Getz ML, Dawson L, Guillen M, Ramirez JJ, Baum MM, Vincent KL.
    PLoS One; 2018 May 01; 13(5):e0197269. PubMed ID: 29758049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.